Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/113482
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBegum, Mahmuda-
dc.contributor.authorChoubey, Mayank-
dc.contributor.authorBabu Tirumalasetty, Munichandra-
dc.contributor.authorArbee, Shahida-
dc.contributor.authorMohabbulla Mohib, Mohammad-
dc.contributor.authorWahiduzzaman, Md-
dc.contributor.authorMamun, Mohammed A.-
dc.contributor.authorBorhan Uddin, Mohammad-
dc.contributor.authorSarif Mohiuddin, Mohammad-
dc.date.accessioned2024-01-24T11:52:30Z-
dc.date.available2024-01-24T11:52:30Z-
dc.date.issued2023-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/115437-
dc.identifier.urihttp://dx.doi.org/10.25673/113482-
dc.description.abstractDiabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, presents a formidable global health challenge with its associated complications. Adiponectin, an adipocyte-derived hormone, has emerged as a significant player in glucose metabolism and insulin sensitivity. Beyond its metabolic effects, adiponectin exerts anti-inflammatory, anti-oxidative, and vasoprotective properties, making it an appealing therapeutic target for mitigating diabetic complications. The molecular mechanisms by which adiponectin impacts critical pathways implicated in diabetic nephropathy, retinopathy, neuropathy, and cardiovascular problems are thoroughly examined in this study. In addition, we explore possible treatment options for increasing adiponectin levels or improving its downstream signaling. The multifaceted protective roles of adiponectin in diabetic complications suggest its potential as a novel therapeutic avenue. However, further translational studies and clinical trials are warranted to fully harness the therapeutic potential of adiponectin in the management of diabetic complications. This review highlights adiponectin as a promising target for the treatment of diverse diabetic complications and encourages continued research in this pivotal area of diabetes therapeutics.eng
dc.language.isoeng-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.ddc610-
dc.titleAdiponectin : a promising target for the treatment of diabetes and its complicationseng
dc.typeArticle-
local.versionTypepublishedVersion-
local.bibliographicCitation.journaltitleLife-
local.bibliographicCitation.volume13-
local.bibliographicCitation.issue11-
local.bibliographicCitation.pagestart1-
local.bibliographicCitation.pageend16-
local.bibliographicCitation.publishernameMDPI-
local.bibliographicCitation.publisherplaceBasel-
local.bibliographicCitation.doi10.3390/life13112213-
local.subject.keywordsadiponectin; AdipoRs; diabetes; pancreatic islets; single-cell RNAseq-
local.openaccesstrue-
dc.identifier.ppn1878882988-
cbs.publication.displayform2023-
local.bibliographicCitation.year2023-
cbs.sru.importDate2024-01-24T11:51:39Z-
local.bibliographicCitationEnthalten in Life - Basel : MDPI, 2011-
local.accessrights.dnbfree-
Appears in Collections:Open Access Publikationen der MLU

Files in This Item:
File Description SizeFormat 
life-13-02213.pdf3.74 MBAdobe PDFThumbnail
View/Open